NEXI NexImmune Inc.

15.09
+0.11  (+1%)
Previous Close 14.98
Open 15.05
52 Week Low 16
52 Week High 28
Market Cap $340,720,415
Shares 22,579,219
Float 17,544,408
Enterprise Value $243,164,559
Volume 71,243
Av. Daily Volume 35,783
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
NEXI-002
Multiple Myeloma
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
NEXI-001
Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS) after allogeneic HCT
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 at 9:20 a.m. Eastern time.

    The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations. A replay will be available on the NexImmune website following the presentation.

    About NexImmune

    NexImmune is a clinical-stage biotechnology…

    GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 at 9:20 a.m. Eastern time.

    The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations. A replay will be available on the NexImmune website following the presentation.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Contacts

    Investors:

    Chad Rubin, SVP Corporate Affairs

    NexImmune, Inc.

    646.319.3261



    Primary Logo

    View Full Article Hide Full Article
  2. GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB). The SAB is comprised of distinguished academic leaders in the fields of immuno-oncology, immunology and T cell biology and their expertise spans the disciplines of basic research, translational science and clinical drug development.

    NexImmune's SAB members include:

    Jeff S. Weber, MD, PhD (Chair), Deputy Director and Head, Experimental Therapeutics, Co-Director of the Melanoma Research Program, Laura and…

    GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB). The SAB is comprised of distinguished academic leaders in the fields of immuno-oncology, immunology and T cell biology and their expertise spans the disciplines of basic research, translational science and clinical drug development.

    NexImmune's SAB members include:

    Jeff S. Weber, MD, PhD (Chair), Deputy Director and Head, Experimental Therapeutics, Co-Director of the Melanoma Research Program, Laura and Isaac Comprehensive Perlmutter Cancer Center at NYU Langone Health; Professor of Medicine, NYU Grossman School of Medicine.

    Kevan Herold, MD, C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology), Yale University; Deputy Director, Yale Center for Clinical Investigation; Co-Director, Yale Diabetes Center.

    Michelle Krogsgaard, PhD, Associate Professor in the Department of Pathology, Co-Leader Tumor Immunology Program, Laura and Isaac Perlmutter Comprehensive Cancer Center at NYU Grossman School of Medicine.

    Yi Lin, MD, PhD., Associate Professor of Medicine, Division of Hematology, Department of Internal Medicine, Mayo Clinic Cancer Center; Consultant, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic; Chair, Cell Therapy Cross-Disciplinary Group, Mayo Clinic Cancer Center.

    Andreas Mackensen, MD, Director, Department of Hematology/Oncology, University Hospital of Erlangen, Erlangen, Germany.

    Marcela Maus, MD, PhD, Associate Professor of Medicine, Mass General Cancer Center at Harvard Medical School; Director of Cellular Immunotherapy, Mass General Cancer Center; Paula O'Keefe Chair in Oncology, Mass General Cancer Center.

    Miguel Perales, MD, Chief, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center; Associate Professor of Medicine, Weill Cornell Medical College.

    Anil K. Rustgi, MD, Director, Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center.

    Jonathan Schneck, MD, PhD, Professor, Department of Pathology, Medicine and Oncology, The Johns Hopkins University School of Medicine; Director, The Johns Hopkins Translational ImmunoEngineering Center; Co-founder NexImmune.

    David Samuel diCapua Siegel, MD, PhD, Chief, Division of Multiple Myeloma John Theurer Cancer Center, Hackensack University Medical Center; Founding Director, Institute for Multiple Myeloma, Center for Discover and Innovation, Hackensack Meridian Health.

    Juan Varela, MD, PhD, Medical Director of Blood and Marrow Transplant Program and Cellular Therapy Facility, Advent Health Cancer Institute.

    "I am honored to be working with these established experts who will advise us on NexImmune's current and future research and clinical activities utilizing our AIM nanotechnology platform," said Jerry Zeldis, EVP of R&D. "Their combined expertise in oncology, immunology, translational science and clinical development will help us advance our pipeline and get significant treatments to patients facing debilitating diseases."

    For more information, visit https://www.neximmune.com/our-company/scientific-advisory-board/

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Forward Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    Contacts

    Investors:

    Chad Rubin, SVP Corporate Affairs

    NexImmune, Inc.

    646.319.3261

    Media:

    Mike Beyer

    Sam Brown Inc. Healthcare Communications

    312.961.2502



    Primary Logo

    View Full Article Hide Full Article
  3. GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually from June 4 – June 8, 2021.

    Poster Presentation:

    Title: Preliminary Analysis of a Phase 1/2 Study of NEXI-001 Donor-Derived Multi-Antigen-Specific CD8+ T Cell Treatment of Relapsed Acute Myeloid Leukemia (AML) After Allogeneic Hematopoietic Cell Transplantation…

    GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually from June 4 – June 8, 2021.

    Poster Presentation:

    Title: Preliminary Analysis of a Phase 1/2 Study of NEXI-001 Donor-Derived Multi-Antigen-Specific CD8+ T Cell Treatment of Relapsed Acute Myeloid Leukemia (AML) After Allogeneic Hematopoietic Cell Transplantation (HCT)

    Abstract #: 2538

    Session Title: Poster Session: Developmental Therapeutics – Immunotherapy

    Authors: Monzr M. Al Malki, MD1, Sumithira Vasu, MBBS2, Dipenkumar Modi, MD3, Miguel-Angel Perales, MD4, Megan Nelson, RN, BSN5, Donna Bui1, Vineetha Edavana, PhD6, Sojung Kim, PhD6, Lauren Suarez, PhD6, Mathias Oelke, PhD6, Robert D. Knight, MD6, and Juan C. Varela, MD, PhD5

    (1) Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA, (2)Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, (3)Division of Oncology, Karmanos Cancer Center/ Wayne State University, Detroit, MI, (4)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, (5)Advent Health Blood and Marrow Transplant Program, Orlando, FL, (6)NexImmune Inc, Gaithersburg, MD.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Forward Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    Contacts

    Investors and Media:

    Chad Rubin, SVP Corporate Affairs

    NexImmune, Inc.

    646.319.3261



    Primary Logo

    View Full Article Hide Full Article
    • Advancing two lead product candidates in Phase 1/2 clinical trials
    • Completed successful $126M initial public offering (IPO) in February 2021
    • Additional clinical and preclinical data anticipated in the second half of 2021

    GAITHERSBURG, Md., May 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for the first quarter of 2021.

    "With a strong cash position following our successful IPO in February, we remain focused on completing enrollment in our clinical trials for NEXI-001 and NEXI-002, and we expect to present…

    • Advancing two lead product candidates in Phase 1/2 clinical trials
    • Completed successful $126M initial public offering (IPO) in February 2021
    • Additional clinical and preclinical data anticipated in the second half of 2021

    GAITHERSBURG, Md., May 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for the first quarter of 2021.

    "With a strong cash position following our successful IPO in February, we remain focused on completing enrollment in our clinical trials for NEXI-001 and NEXI-002, and we expect to present additional clinical data at scientific conferences during 2021 for each," said Scott Carmer, Chief Executive Officer. "We are also advancing new cell therapy programs targeting solid tumors and have initiated IND-enabling pre-clinical experiments that will support the initial application of our ‘AIM Injectable' modality. We look forward to providing further updates as these important programs mature."

    Select 1Q 2021 Business Highlights

    • On February 17, 2021, NexImmune completed a successful IPO and raised gross proceeds of $126M. The IPO was oversubscribed and priced at the top of the range.
    • NexImmune announced the appointments of Robert Knight, MD as Chief Medical Officer; Jerome Zeldis, MD, PhD as Executive Vice President, Research and Development; Jeffery Weber, MD, PhD as Chief Scientific Advisor and Scientific Advisory Board Chair; Chad Rubin as SVP of Corporate Affairs; and Grant Verstandig as a member of its Board of Directors.
    • NEXI-001 and NEXI-002 are both in Phase 1/2 clinical trials. The Company will share preliminary data from the initial safety cohorts of both trials at the 2021 ASCO Annual Meeting and EHA2021 Virtual Congress for NEXI-001 and NEXI-002, respectively, with additional results for each trial in Q421.

    Select 1Q 2021 Financial Highlights

    Cash and cash equivalents for the company as of March 31, 2021 were $118.1M, compared to $5.0M at December 31, 2020. Based upon its current operating plans and cash and cash equivalents the Company expects to have sufficient capital to fund its operating expenses and capital expenditure requirements through the second quarter of 2022.

    Research and development expenses were $6.0M in the first quarter of 2021, compared to $4.3M for the same period in the prior year. The increase in R&D expenses were mainly attributable to costs for the two clinical trials as well as personnel-related expenses driven by increased headcount, offset partially by reduced preclinical and regulatory-related spending.

    General and administrative expenses were $4.1M, compared to $2.1M for the same period the prior year. The increase was due primarily to increases in headcount and fees related to professional and consulting services.

    Net loss, according to generally accepted accounting principles in the U.S. (GAAP), was $8.5M for the quarter, or a basic and diluted GAAP loss per share of $0.71. This compared to a net loss of $6.3M for the same period the prior year.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Forward Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our results of operations for the three months ended March 31, 2021; the sufficiency of the Company's current cash and cash equivalents to fund its planned operations through the second quarter of 2022; our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.





    NEXIMMUNE, INC.

    BALANCE SHEETS

      March 31,

    2021
     December 31,

    2020
      unaudited  
    ASSETS    
    Current assets:     
    Cash and cash equivalents $118,102,945  $5,031,079 
    Restricted cash  67,500   67,500 
    Prepaid expenses and other current assets  4,788,019   3,293,858 
    Total current assets  122,958,464   8,392,437 
    Property and equipment, net  3,584,412   2,885,260 
    Other non-current assets  23,373   23,373 
    Total assets $126,566,249  $11,301,070 
    LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT
    Current liabilities:    
    Accounts payable $2,406,537  $2,760,129 
    Accrued expenses  2,842,998   2,603,027 
    Derivative liability     1,702,359 
    Other current liabilities  843,619   843,619 
    Convertible notes issued to related parties     7,324,267 
    Convertible notes     11,793,397 
    Total current liabilities  6,093,154   27,026,798 
    Deferred rent, net of current portion  11,764   23,529 
    Other non-current liabilities     4,935 
    Total liabilities  6,104,918   27,055,262 
    Commitments and contingencies    
    Redeemable convertible preferred stock    
    Series A Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of March 31, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of $42,314,789 as of December 31, 2020.     35,047,435 
    Series A-2 Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of March 31, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020.

        Liquidation value of $8,683,746 as of December 31, 2020
         7,685,865 
    Series A-3 Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of March 31, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020.

        Liquidation value of $11,699,176 as of December 31, 2020.
         10,887,449 
    Total redeemable convertible preferred stock     53,620,749 
    Stockholders' deficit    
    Common Stock, $0.0001 par value, 250,000,000 shares authorized, 22,579,219 issued and outstanding as of March 31, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020.  2,258   126 
    Additional paid-in-capital  205,847,571   8,206,938 
    Accumulated deficit  (85,388,498)  (77,582,005)
    Total stockholders' deficit  120,461,331   (69,374,941)
    Total liabilities, redeemable convertible preferred stock and stockholders' deficit $126,566,249  $11,301,070 





    NEXIMMUNE, INC.

    STATEMENTS OF OPERATIONS

    (unaudited)

      Three Months Ended March 31,
       2021   2020 
    Revenue $        —  $        — 
    Operating expenses:    
    Research and Development  6,012,608   4,272,167 
    General and Administrative  4,057,592   2,088,401 
    Total operating expenses  10,070,200   6,360,568 
    Loss from operations  (10,070,200)  (6,360,568)
    Other (expense) income:    
    Interest income  3,613   18,684 
    Interest expense  (904,119)  (989)
    Change in fair value of derivative liability  2,424,877    
    Other income (expense)  (722)  27,365 
    Other income (expense)  1,523,649   45,060 
    Net loss $        (8,546,551) $        (6,315,508)
    Accumulated dividends on Redeemable Convertible Preferred Stock  (377,562)  (815,516)
    Net loss available to common stockholders' $        (8,924,113) $        (7,131,024)
    Basic and diluted net loss available to common stockholders per common share $        (0.71) $        (5.68)
    Basic and diluted weighted-average number of common shares outstanding  12,633,123   1,254,681 





    STATEMENTS OF COMPREHENSIVE LOSS


    (unaudited)

      For the Three Months Ended March 31,
       2021   2020 
    Net loss $        (8,546,551) $        (6,315,508)
    Other comprehensive loss:    
    Unrealized (loss) gain on available-for-sale marketable securities, net of tax     (506)
    Comprehensive loss $        (8,546,551) $        (6,316,014)

    Contacts

    Investors:

    Chad Rubin, SVP Corporate Affairs

    NexImmune, Inc.

    646.319.3261

    Media:

    Mike Beyer

    Sam Brown Inc. Healthcare Communications

    312.961.2502

     



    Primary Logo

    View Full Article Hide Full Article
    • Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout

    GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within…

    • Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout

    GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.

    "Chad is an important addition to our senior leadership team," said Scott Carmer, Chief Executive Officer of NexImmune. "We welcome his breadth of experience in the biotech industry, well-established relationships with the financial community and deep understanding of financial communications and capital markets. He served as a valuable strategic consultant to the company for six years as part of the Solebury Trout, and we look forward to his continued contribution as we continue to evolve NexImmune from a private, development-stage company to a public, clinically driven organization advancing cell-mediated immunotherapy drug candidates for the benefit of patients facing a number of difficult-to-treat diseases."

    Mr. Rubin joins NexImmune from Solebury Trout, a leading investor relations, strategic advisory and capital markets advisor in the life sciences sector, where he was a Managing Director. He most recently served as co-head of the Trout team that provides strategic counsel on investor relations and communication strategies, while also serving as an advisor on capital formation transactions for both private and public biotechnology companies. Mr. Rubin also sits on the Board of Trustees for the Histiocytosis Association, an organization addressing the needs of patients and families dealing with histiocytic disorders and leading the search for a cure.

    "This is an exciting time to join NexImmune. The Company's proprietary nanotechnology platform has the potential to positively impact patients facing cancer, autoimmune disorders and infectious diseases. I am honored to be able to contribute to the team as we advance our first two product candidates in Phase 1/2 clinical trials," said Mr. Rubin.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is its proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. NexImmune's precision technology and unique scientific approach offer promise in restoring hope for patients suffering from cancer, autoimmune disorders, and infectious diseases by directing specific immune responses to attack or moderate cells and other infectious agents causing the underlying disease.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. In these clinical trials, AIM constructed nanoparticles employ natural biology to engage, activate, and expand endogenous T cells in ways that combine the anti-tumor attributes of antigen-specific precision, potency, and long-term persistence with reduced potential for off-target toxicities.

    For more information, visit www.neximmune.com.

    Forward Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our results of operations for the year ended December 31, 2020; the sufficiency of the Company's current cash and cash equivalents to fund its planned operations through the second quarter of 2022; our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    Contacts

    Investors:

    Chad Rubin

    NexImmune

    646-378-2947

    Media:

    Mike Beyer

    Sam Brown Inc. Healthcare Communications

    312-961-2502



    Primary Logo

    View Full Article Hide Full Article
View All NexImmune Inc. News